

Cezary Wojcik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8382611/publications.pdf>

Version: 2024-02-01

59
papers

2,220
citations

257101

24
h-index

223531

46
g-index

63
all docs

63
docs citations

63
times ranked

3348
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel podophyllotoxin and benzothiazole derivative induces transitional morphological and functional changes in HaCaT cells. <i>Toxicology in Vitro</i> , 2021, 73, 105144.	1.1	9
2	Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1437-1449.	1.2	13
3	Emerging lipid lowering agents targeting LDL cholesterol. <i>Postgraduate Medicine</i> , 2020, 132, 433-440.	0.9	5
4	Bridging the Gap Between Cardiology and Family Medicine. <i>Circulation</i> , 2019, 140, 709-711.	1.6	3
5	Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors. <i>Current Cardiology Reports</i> , 2019, 21, 130.	1.3	38
6	Application of PCSK9 Inhibitors in Practice. <i>Circulation Research</i> , 2019, 124, 32-37.	2.0	61
7	Translating AHA/ACC cholesterol guidelines into meaningful risk reduction. <i>Journal of Family Practice</i> , 2019, 68, 206;210;212;214;217;221B.	0.2	0
8	Co-occurrence of heterozygous CREB3L3 and APOA5 nonsense variants and polygenic risk in a patient with severe hypertriglyceridemia exacerbated by estrogen administration. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1146-1150.	0.6	4
9	Mucosal delivery systems of antihypertensive drugs: A practical approach in general practice. <i>Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia</i> , 2018, 162, 71-78.	0.2	5
10	Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9. <i>Journal of Clinical Lipidology</i> , 2017, 11, 667-673.	0.6	40
11	Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. <i>Postgraduate Medicine</i> , 2017, 129, 801-810.	0.9	2
12	Application of PCSK9 Inhibitors in Practice. <i>Circulation Research</i> , 2017, 121, 499-501.	2.0	26
13	Dyslipidemias. , 2017, , 1637-1647.		3
14	The Cholesterol Dilemma: Treating the Risk or Treating to LDL-C Goal?. <i>American Family Physician</i> , 2017, 95, 66-69.	0.1	1
15	Modulation of adipocyte differentiation by omega-3 polyunsaturated fatty acids involves the ubiquitin-proteasome system. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 590-599.	1.6	41
16	Rubinstein-Taybi syndrome associated with Chiari type I malformation caused by a large 16p13.3 microdeletion: A contiguous gene syndrome?. <i>American Journal of Medical Genetics, Part A</i> , 2010, 152A, 479-483.	0.7	26
17	Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib. <i>American Journal of Pathology</i> , 2010, 176, 2658-2668.	1.9	115
18	Functional differences between two major ubiquitin receptors in the proteasome; S5a and hRpn13. <i>Biochemical and Biophysical Research Communications</i> , 2010, 396, 425-428.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response. <i>Cancer Research</i> , 2009, 69, 4235-4243.	0.4	96
20	Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. <i>International Journal of Emergency Medicine</i> , 2009, 2, 217-225.	0.6	70
21	Analysis of Npl4 deletion mutants in mammalian cells unravels new Ufd1-interacting motifs and suggests a regulatory role of Npl4 in ERAD. <i>Experimental Cell Research</i> , 2008, 314, 2715-2723.	1.2	13
22	The role of sperm proteasomes during sperm aster formation and early zygote development: implications for fertilization failure in humans. <i>Human Reproduction</i> , 2008, 23, 573-580.	0.4	72
23	Decreased ER-associated degradation of $\hat{\pm}$ -TCR induced by Grp78 depletion with the SubAB cytotoxin. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 2865-2879.	1.2	27
24	A novel function of VCP (valosin-containing protein; p97) in the control of N-glycosylation of proteins in the endoplasmic reticulum. <i>Archives of Biochemistry and Biophysics</i> , 2007, 462, 62-73.	1.4	15
25	Ufd1 $\hat{\pm}$ Npl4 is a negative regulator of cholera toxin retrotranslocation. <i>Biochemical and Biophysical Research Communications</i> , 2007, 355, 1087-1090.	1.0	16
26	TNF potentiates anticancer activity of bortezomib (Velcade $\hat{\circ}$) through reduced expression of proteasome subunits and dysregulation of unfolded protein response. <i>International Journal of Cancer</i> , 2007, 121, 431-441.	2.3	26
27	Destabilization of the VCP-Ufd1-Npl4 complex is associated with decreased levels of ERAD substrates. <i>Experimental Cell Research</i> , 2006, 312, 2921-2932.	1.2	36
28	Valosin-containing Protein (p97) Is a Regulator of Endoplasmic Reticulum Stress and of the Degradation of N-End Rule and Ubiquitin-Fusion Degradation Pathway Substrates in Mammalian Cells. <i>Molecular Biology of the Cell</i> , 2006, 17, 4606-4618.	0.9	165
29	Modulation of Gene Expression by RNAi. , 2005, 108, 381-394.		9
30	Proteasome Regulator, PA700 (19S Regulatory Particle). , 2005, , 288-316.		0
31	RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/proteasome-dependent proteolysis. <i>Journal of Cell Science</i> , 2004, 117, 281-292.	1.2	227
32	Ubiquitin-Proteasome System and Proteasome Inhibition: New Strategies in Stroke Therapy. <i>Stroke</i> , 2004, 35, 1506-1518.	1.0	132
33	AAF-cmk sensitizes tumor cells to trail-mediated apoptosis. <i>Leukemia Research</i> , 2004, 28, 53-61.	0.4	4
34	Eastern Europe: progress stifled by the old guard. <i>Nature</i> , 2004, 427, 196-196.	13.7	3
35	Aggregate formation in the spinal cord of mutant SOD1 transgenic mice is reversible and mediated by proteasomes. <i>Journal of Neurochemistry</i> , 2004, 87, 851-860.	2.1	63
36	Intracellular localization of proteasomes. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 579-589.	1.2	305

#	ARTICLE	IF	CITATIONS
37	Analysis of Drosophila 26 S Proteasome Using RNA Interference. Journal of Biological Chemistry, 2002, 277, 6188-6197.	1.6	103
38	Regulation of apoptosis by the ubiquitin and proteasome pathway. Journal of Cellular and Molecular Medicine, 2002, 6, 25-48.	1.6	102
39	Ubiquitin: no longer the chosen one. Trends in Cell Biology, 2002, 12, 109.	3.6	0
40	VCP – the missing link in protein degradation?. Trends in Cell Biology, 2002, 12, 212.	3.6	5
41	The power of crystals: SCF structure demystified. Trends in Cell Biology, 2002, 12, 323.	3.6	0
42	Two blades of a sword: degradation coupled to deubiquitination. Trends in Cell Biology, 2002, 12, 549.	3.6	1
43	Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. International Journal of Cancer, 2002, 97, 746-750.	2.3	16
44	Viruses at the centrosome: the birthplace of antigenic peptides?. Trends in Cell Biology, 2001, 11, 281-282.	3.6	0
45	KO: –The Lord of the Rings–™. Trends in Cell Biology, 2000, 10, 134-135.	3.6	0
46	Dying in the cradle. Trends in Cell Biology, 2000, 10, 272.	3.6	0
47	How is the gate to the proteasome opened?. Trends in Cell Biology, 2000, 10, 312-313.	3.6	0
48	Dipeptides: rulers of the N-end rule. Trends in Cell Biology, 2000, 10, 367.	3.6	0
49	Ubiquitin – a killer, which is also a midwife. Trends in Cell Biology, 2000, 10, 414.	3.6	0
50	TIME to be degraded. Trends in Cell Biology, 2000, 10, 53.	3.6	0
51	Separation of cathepsin A-like enzyme and the proteasome: evidence that lactacystin/β-lactone is not a specific inhibitor of the proteasome. International Journal of Biochemistry and Cell Biology, 2000, 32, 747-757.	1.2	45
52	Lovastatin and simvastatin are modulators of the proteasome. International Journal of Biochemistry and Cell Biology, 2000, 32, 957-965.	1.2	40
53	Ubiquitin- and proteasome-dependent pathway of protein degradation as an emerging therapeutic target. Expert Opinion on Therapeutic Targets, 2000, 4, 89-111.	1.0	7
54	LOVASTATIN INDUCES MITOTIC ABNORMALITIES IN VARIOUS CELL LINES. Cell Biology International, 1999, 23, 51-60.	1.4	21

#	ARTICLE	IF	CITATIONS
55	Proteasome activator subunit PA28 $\hat{\alpha}$ and related Ki antigen (PA28 $\hat{\alpha}^3$) are absent from the nuclear fraction purified by sucrose gradient centrifugation. <i>International Journal of Biochemistry and Cell Biology</i> , 1999, 31, 273-276.	1.2	8
56	Changes in proteasome expression and activity during differentiation of neuronal precursor Ntera 2 clone D1 cells. <i>Neurochemistry International</i> , 1999, 34, 131-136.	1.9	10
57	Proteasome activator (PA28) subunits, $\hat{\alpha}$, $\hat{\alpha}^2$ and $\hat{\alpha}^3$ (Ki antigen) in NT2 neuronal precursor cells and HeLa S3 cells. <i>European Journal of Cell Biology</i> , 1998, 77, 151-160.	1.6	71
58	Lactacystin, a Specific Inhibitor of the Proteasome, Inhibits Human Platelet Lysosomal Cathepsin A-like Enzyme. <i>Biochemical and Biophysical Research Communications</i> , 1997, 234, 729-732.	1.0	98
59	Rpt2. <i>The AFCS-nature Molecule Pages</i> , 0, , .	0.2	0